Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
Background: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectivel...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-06-01
|
Series: | Dementia and Geriatric Cognitive Disorders Extra |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/477343 |
_version_ | 1818418151030784000 |
---|---|
author | Tomomichi Iizuka Kozo Morimoto Yuka Sasaki Masashi Kameyama Atsuyuki Kurashima Kazumasa Hayasaka Hideo Ogata Hajime Goto |
author_facet | Tomomichi Iizuka Kozo Morimoto Yuka Sasaki Masashi Kameyama Atsuyuki Kurashima Kazumasa Hayasaka Hideo Ogata Hajime Goto |
author_sort | Tomomichi Iizuka |
collection | DOAJ |
description | Background: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed 18F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. Methods: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled. The hypometabolic patterns were evaluated with stereotaxic statistical analysis and region of interest analysis. Results: Before treatment, AD-type hypometa bolism was observed in 12 patients. The FDG uptake in the posterior cingulate cortex (PCC) was improved or stabilized in 6 patients after 12-month therapy (450 mg/day), whereas another 6 patients with 6-month therapy showed a decreased FDG uptake in the PCC. In patients who underwent FDG-PET only after treatment, the metabolic decline in the PCC was significantly milder in patients with ≥12 months of rifampicin treatment than in those with 6 months of treatment. Multiple regression analysis revealed that the dose of rifampicin and treatment duration significantly influenced FDG uptake in the PCC. Conclusion: The preventive effect of rifampicin depended on the dose and the treatment duration, and the effect needs at least 450 mg daily for 1 year. |
first_indexed | 2024-12-14T12:18:07Z |
format | Article |
id | doaj.art-e76ca4e46eb4479d8ba6539a8e4bc61e |
institution | Directory Open Access Journal |
issn | 1664-5464 |
language | English |
last_indexed | 2024-12-14T12:18:07Z |
publishDate | 2017-06-01 |
publisher | Karger Publishers |
record_format | Article |
series | Dementia and Geriatric Cognitive Disorders Extra |
spelling | doaj.art-e76ca4e46eb4479d8ba6539a8e4bc61e2022-12-21T23:01:35ZengKarger PublishersDementia and Geriatric Cognitive Disorders Extra1664-54642017-06-017220421410.1159/000477343477343Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up StudyTomomichi IizukaKozo MorimotoYuka SasakiMasashi KameyamaAtsuyuki KurashimaKazumasa HayasakaHideo OgataHajime GotoBackground: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed 18F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. Methods: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled. The hypometabolic patterns were evaluated with stereotaxic statistical analysis and region of interest analysis. Results: Before treatment, AD-type hypometa bolism was observed in 12 patients. The FDG uptake in the posterior cingulate cortex (PCC) was improved or stabilized in 6 patients after 12-month therapy (450 mg/day), whereas another 6 patients with 6-month therapy showed a decreased FDG uptake in the PCC. In patients who underwent FDG-PET only after treatment, the metabolic decline in the PCC was significantly milder in patients with ≥12 months of rifampicin treatment than in those with 6 months of treatment. Multiple regression analysis revealed that the dose of rifampicin and treatment duration significantly influenced FDG uptake in the PCC. Conclusion: The preventive effect of rifampicin depended on the dose and the treatment duration, and the effect needs at least 450 mg daily for 1 year.http://www.karger.com/Article/FullText/477343Preventive therapyAlzheimer diseaseFDG-PETRifampicinAmyloid-βOligomer |
spellingShingle | Tomomichi Iizuka Kozo Morimoto Yuka Sasaki Masashi Kameyama Atsuyuki Kurashima Kazumasa Hayasaka Hideo Ogata Hajime Goto Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study Dementia and Geriatric Cognitive Disorders Extra Preventive therapy Alzheimer disease FDG-PET Rifampicin Amyloid-β Oligomer |
title | Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study |
title_full | Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study |
title_fullStr | Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study |
title_full_unstemmed | Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study |
title_short | Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study |
title_sort | preventive effect of rifampicin on alzheimer disease needs at least 450 mg daily for 1 year an fdg pet follow up study |
topic | Preventive therapy Alzheimer disease FDG-PET Rifampicin Amyloid-β Oligomer |
url | http://www.karger.com/Article/FullText/477343 |
work_keys_str_mv | AT tomomichiiizuka preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT kozomorimoto preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT yukasasaki preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT masashikameyama preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT atsuyukikurashima preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT kazumasahayasaka preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT hideoogata preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy AT hajimegoto preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy |